Bass now targeting Imbruvica patent

Pharmacyclics Inc. (NASDAQ:PCYC) became the latest company to face a patent challenge from hedge fund manager Kyle Bass, joining Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Shire plc (LSE:SHP; NASDAQ:SHPG) and Acorda Therapeutics Inc. (NASDAQ:ACOR).

Coalition for Affordable Drugs IV, an entity associated with Bass, filed an inter partes review (IPR) on Monday with the U.S. Patent and Trademark Office challenging U.S. Patent No. 8,754,090, which covers Imbruvica ibrutinib and expires in 2031. The '090 patent is one of 13 Orange Book-listed patents covering Imbruvica and the last to expire; the remainder expire in 2026. ...